Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Rheumatology Drug Updates: Efficacy & Safety of Guselkumab, Plus FX006 for Knee OA

Kelly April Tyrrell  |  Issue: February 2017  |  

Adverse events were mild and balanced across treatment and placebo study arms. No serious adverse events occurred.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ADVERTISEMENT
SCROLL TO CONTINUE

Acknowledgment: Thanks to Lara C. Pullen, PhD, a medical writer based in the Chicago area, for her assistance in writing the Efficacy & Safety of Guselkumab section of this column.

References

  1. Deodhar AA, Gottlieb AB, Boehncke WH, et al. Efficacy and safety results of guselkumab, an anti-IL23 monoclonal antibody, in patients with active psoriatic arthritis over 24 weeks: A phase 2a, randomized, double-blind, placebo-controlled study [abstract]. Arthritis Rheumatol. 2016;68(suppl 10).
  2. Stendahl M. Fast-growing Burlington biotech Flexion files for approval of lead drug. Boston Business Journal. 2016 Dec 12.

Related Articles

    Case Report: A Psoriatic Arthritis Patient with Dactylitis & Enthesitis

    A 36-year-old woman presented at the Johns Hopkins Arthritis Center for a second opinion regarding a diagnosis of psoriatic arthritis (PsA). One year prior to our evaluation, she had developed pain and stiffness in her hands, feet, knees, ankles, elbows and shoulders. She had mild plaque psoriasis of the scalp and base of the neck,…

    Guselkumab Studied to Treat RA, Plaque Psoriasis

    Guselkumab Studied to Treat RA & Plaque Psoriasis Guselkumab (GUS) is a subcutaneously administered monoclonal antibody that targets interleukin (IL) 23.1 It is being investigated in a Phase 2 study to treat rheumatoid arthritis (RA) and moderate to severe plaque psoriasis (PsA). On June 11, 2015, at the 2015 meeting of the European League Against…